Video

MSI Testing Is Crucial in Colorectal Cancer

Author(s):

Michael J. Overman, M.D.

Genetic testing – particularly for microsatellite instability (MSI) – is an important step for all patients diagnosed with colorectal cancer.

Genetic testing — particularly for microsatellite instability (MSI) – is an important step for all patients diagnosed with colorectal cancer (CRC), says Michael J. Overman, M.D., associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center.

Recent findings presented at the 2017 Gastrointestinal Cancers Symposium found that the immunotherapy agent Opdivo (nivolumab) drastically improved response rates and progression-free survival in patients with metastatic CRC who tested positive for MSI. Since the agent is so promising, it is important to identify patients who would benefit from this treatment.

Related Videos
Image of Dr. Braun.
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Dr. Michael Bogenschutz
Photo credit: Max Mumby/Indigo via Getty Images
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine, in the Department of Medicine, at Beth Israel Deaconess Medical Center in Boston.
Dr. Stephanie Alice Baker
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.
Dr. Laura Dawson, a professor and chair of the department of Radiation Oncology at the University of Toronto, and a practicing radiation oncologist in the Radiation Medicine Program at Princess Margaret Cancer Center, University Health Network in Toronto.
Related Content
Image of man holding his stomach.
January 24th 2025

Second Cancer Risk Heightened After Appendiceal Adenocarcinoma Diagnosis

Spencer Feldman
Adults with primary primary appendiceal adenocarcinoma face a higher risk of developing a second primary cancer, including colorectal and prostate cancers.
Teri Greige with medals
February 16th 2023

The Sport of Cancer: How One Survivor Linked Ironman Training and Colorectal Cancer

Brielle Benyon
Teri Griege completed an Ironman triathlon in 2009, and less than a month later received a stage 4 colorectal cancer diagnosis. In this episode of Cancer Horizons, she shared her story.
Image of blood-based test.
January 22nd 2025

Understanding the Concept of MRD for Patients With Cancer

Ryan Scott
Dr. Christopher Flowers discusses MRD testing in cancer care, why this is an important concept to understand and how it relates to recurrence in patients.
‘Let’s Go After This Thing and Fight’ Urges a Long-Time Survivor of Early-Onset CRC
January 27th 2022

‘Let’s Go After This Thing and Fight’ Urges a Long-Time Survivor of Early-Onset CRC

Jamie Cesanek
In this episode of the “Cancer Horizons” podcast, a woman living with colorectal cancer who was diagnosed 14 years ago at age 29 discusses what it was like to be the youngest person in the treatment room, and how she found another community of young survivors.
Illustration of man with grey hair.
January 17th 2025

Carrying the Torch: From Colorectal Cancer Survivor to Advocate

Joe Bullock
As someone who has overcome colorectal cancer, I reflect on the support I received from others and vow to continue their legacy of advocacy.
Image of FDA.
January 16th 2025

FDA Approves Lumakras with Vectibix in KRAS G12C+ Colorectal Cancer

Alex Biese
The FDA has approved Lumakras with Vectibix for adults with KRAS G12C-mutated metastatic colorectal cancer who received chemotherapy.